Send the link below via email or IMCopy
Present to your audienceStart remote presentation
- Invited audience members will follow you as you navigate and present
- People invited to a presentation do not need a Prezi account
- This link expires 10 minutes after you close the presentation
- A maximum of 30 users can follow your presentation
- Learn more about this feature in our knowledge base article
Do you really want to delete this prezi?
Neither you, nor the coeditors you shared it with will be able to recover it again.
Make your likes visible on Facebook?
Connect your Facebook account to Prezi and let your likes appear on your timeline.
You can change this under Settings & Account at any time.
Transcript of Case Competition
3. Retention Leaders of Opinion
Strategy consists in pressuring to PUSH product to consumers Lilly Cardiovascular: Innovation requires tough decisions Diagnosis:
Current Situation Context Product Marketing Analysis Mexico:
50 Million Mexicans adults suffer of Dyslipidemia
44% of adult population
Only 5% is treated
78% deaths related to cardiovascular diseases
Movement: sole physician-oriented to patient focus strategies
Patient understanding of disease is becoming critical
Generics are successfully attacking market. Differentiation? Consumer Doesn’t perceive any benefits.
Drawbacks are immediate
Non- loyal to brand/medication. Lilly Physicians Lilly new in statin market
Focus on innovation
Position a cardiovascular franchise Competitors
Efficacy and safety of statins are no longer differentiators, but “givens”.
"Waste" time to explain about the disease and treatment. Crestor (Astra Zeneca): 30% SOM. About to lose patent.
Lipitor – Pfizer: 29% SOM. About to lose patent.
Vytorin/Zintrepid – MSD
Generics: cost five times less than branded “super statin”. Recommend use: treat mixed dyslipidemia.
Commonly used by physicians to treat high cholesterol.
Superior safety profile.
USA : "complicated patients". Redevant Proposed Solutions Threaths:
Short-term: Strong competitors
Mid-term: Generics and new develop drugs.
Long-term: Market Orientation Push Strategies Pull Strategies Value Proposition: reinforce intangible components of client satisfaction.
QR Code on existing resources
Similar Medication Boxes (cross-selling)
Link to: Information, ads. QR Code Hooked on Lilly: "Para Ti, Para Mi, Para Dos".
Creates link of preference to Lilly
Exploit new trends to create brand adherence. App:
Alarms and Calendar
This creates Customer Loyalty
Promotes: Retention and drives for continuing treatment Happy-Lilly ever after Cost We expect to gain 15% of the
recent active market.
We will activate 3% of the inactive market . Half will be treated with Redevant.
Revenues of $702.6M in
Profits 638M. 90% Profitable.
In next years we expect 1% growth rate plus 10% of permanence.
Revenues expected of 9.6Billion (2012-2015).
Profit 8.7 Billion (2012-2015)
Cost Yes, we are going to launch.
This is HOW and WHY. Happy Ever After References: http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/vol_2_markets_innovation_regulation_en.pdf